{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:59:47Z","timestamp":1648594787705},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.lpm.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T07:02:25Z","timestamp":1317625345000},"page":"1059-1064","source":"Crossref","is-referenced-by-count":0,"title":["Ralentir la progression de l\u2019insuffisance r\u00e9nale chronique\u00a0: espoirs et d\u00e9ceptions. Le cas de la polykystose r\u00e9nale autosomique dominante"],"prefix":"10.1016","volume":"40","author":[{"given":"St\u00e9phane","family":"Burtey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.08.001_bib0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.08.001_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2005.04.017","article-title":"The prevalence of ESRD treated with renal dialysis in France in 2003","volume":"46","author":"Macron-Nogu\u00e8s","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.08.001_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1\u00a0and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.08.001_bib0025","first-page":"837","article-title":"Polycystic kidneys","volume":"59","author":"Burtey","year":"2009","journal-title":"Rev Prat"},{"key":"10.1016\/j.lpm.2011.08.001_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","article-title":"Management of cerebral aneurysms in autosomal dominant polycystic kidney disease","volume":"13","author":"Pirson","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0040","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.08.001_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2009.13","article-title":"Cardiovascular abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Ecder","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0050","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1681\/ASN.V10112426","article-title":"Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group","volume":"10","author":"Levey","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0055","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal dominant polycystic kidney disease: results of a 7-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0060","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.08.001_bib0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","article-title":"Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study","volume":"57","author":"Patch","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.08.001_bib0070","doi-asserted-by":"crossref","unstructured":"Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009.","DOI":"10.1681\/ASN.2008080882"},{"key":"10.1016\/j.lpm.2011.08.001_bib0075","doi-asserted-by":"crossref","unstructured":"Takiar V, Caplan MJ. Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta 2010.","DOI":"10.1016\/j.bbadis.2010.11.014"},{"key":"10.1016\/j.lpm.2011.08.001_bib0080","doi-asserted-by":"crossref","unstructured":"The polycystic kidney disease 1\u00a0gene encodes a 14kb transcript lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994;77:881\u201398.","DOI":"10.1016\/0092-8674(94)90137-6"},{"key":"10.1016\/j.lpm.2011.08.001_bib0085","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.lpm.2011.08.001_bib0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1083\/jcb.201006173","article-title":"The cell biology of polycystic kidney disease","volume":"191","author":"Chapin","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0095","doi-asserted-by":"crossref","unstructured":"Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2008.","DOI":"10.1016\/B978-1-4160-0252-9.50011-2"},{"key":"10.1016\/j.lpm.2011.08.001_bib0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.physiol.70.113006.100621","article-title":"Polycystins and primary cilia: primers for cell cycle progression","volume":"71","author":"Zhou","year":"2009","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0962-8924(03)00169-7","article-title":"Role of polycystins in renal tubulogenesis","volume":"13","author":"Boletta","year":"2003","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2007.10.037","article-title":"Variation in age at ESRD in autosomal dominant polycystic kidney disease","volume":"51","author":"Reed","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.08.001_bib0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1681\/ASN.2011030284","article-title":"Third-hit signaling in renal cyst formation","volume":"22","author":"Weimbs","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0120","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0092-8674(00)81793-6","article-title":"The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I","volume":"87","author":"Qian","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.lpm.2011.08.001_bib0125","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm1675","article-title":"A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1","volume":"13","author":"Piontek","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2011.08.001_bib0130","doi-asserted-by":"crossref","unstructured":"Takakura A, Contrino L, Zhou X, Bonventre JV, Sun Y, Humphreys BD et al. Renal injury is a third-hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet 2009.","DOI":"10.1093\/hmg\/ddp147"},{"key":"10.1016\/j.lpm.2011.08.001_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng1701","article-title":"Defective planar cell polarity in polycystic kidney disease","volume":"38","author":"Fischer","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.lpm.2011.08.001_bib0140","doi-asserted-by":"crossref","unstructured":"Drummond IA. Polycystins, focal adhesions and extracellular matrix interactions Biochim Biophys Acta 2011.","DOI":"10.1016\/j.bbadis.2011.03.003"},{"key":"10.1016\/j.lpm.2011.08.001_bib0145","doi-asserted-by":"crossref","unstructured":"Terryn S, Ho A, Beauwens R, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease Biochim Biophys Acta 2011.","DOI":"10.1016\/j.bbadis.2011.01.011"},{"key":"10.1016\/j.lpm.2011.08.001_bib0150","doi-asserted-by":"crossref","unstructured":"Abdul-Majeed S, Nauli SM. Calcium-mediated mechanisms of cystic expansion Biochim Biophys Acta 2010.","DOI":"10.1016\/j.bbadis.2010.09.016"},{"key":"10.1016\/j.lpm.2011.08.001_bib0155","unstructured":"Wallace DP. Cyclic AMP-mediated cyst expansion Biochim Biophys Acta 2010."},{"key":"10.1016\/j.lpm.2011.08.001_bib0160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2011.08.001_bib0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.08.001_bib0170","doi-asserted-by":"crossref","unstructured":"Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease Kidney Int 2011.","DOI":"10.1038\/ki.2011.119"},{"key":"10.1016\/j.lpm.2011.08.001_bib0175","doi-asserted-by":"crossref","unstructured":"van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MGH, Hoffmann AL, Dekker HM et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 2009.","DOI":"10.1053\/j.gastro.2009.07.052"},{"key":"10.1016\/j.lpm.2011.08.001_bib0180","doi-asserted-by":"crossref","unstructured":"Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010, [ASN. 2009121291].","DOI":"10.1681\/ASN.2009121291"},{"key":"10.1016\/j.lpm.2011.08.001_bib0185","doi-asserted-by":"crossref","unstructured":"Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, [CJN 05380709].","DOI":"10.2215\/CJN.05380709"},{"key":"10.1016\/j.lpm.2011.08.001_bib0190","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2011.08.001_bib0195","first-page":"6","article-title":"Emerging evidence of a link between the polycystins and the mTOR pathways","volume":"2","author":"Boletta","year":"2009","journal-title":"Pathol Genet"},{"key":"10.1016\/j.lpm.2011.08.001_bib0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0205","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.08.001_bib0210","doi-asserted-by":"crossref","unstructured":"Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010, [NEJMoa1003491].","DOI":"10.1056\/NEJMoa1003491"},{"key":"10.1016\/j.lpm.2011.08.001_bib0215","doi-asserted-by":"crossref","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010, [NEJMoa0907419].","DOI":"10.1056\/NEJMoa0907419"},{"key":"10.1016\/j.lpm.2011.08.001_bib0220","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0225","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2011.08.001_bib0230","doi-asserted-by":"crossref","unstructured":"Xia S, Li X, Johnson T, Seidel C, Wallace DP, Li R. Polycystin-dependent fluid flow sensing targets histone deacetylase 5\u00a0to prevent the development of renal cysts. Development 2010.","DOI":"10.1242\/dev.049437"},{"key":"10.1016\/j.lpm.2011.08.001_bib0235","doi-asserted-by":"crossref","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD, Li H, Zhang L et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 2011.","DOI":"10.1073\/pnas.1011498108"},{"key":"10.1016\/j.lpm.2011.08.001_bib0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1998.00067.x","article-title":"Smoking as a risk factor for end-stage renal failure in men with primary renal disease","volume":"54","author":"Orth","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.08.001_bib0245","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/01.ASN.0000025282.48298.7B","article-title":"The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease","volume":"13","author":"Belibi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.08.001_bib0250","doi-asserted-by":"crossref","unstructured":"Wang CJ, Creed C, Winklhofer FT, Grantham JJ. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 2010.","DOI":"10.2215\/CJN.03950510"},{"key":"10.1016\/j.lpm.2011.08.001_bib0255","doi-asserted-by":"crossref","unstructured":"Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine camp in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010.","DOI":"10.2215\/CJN.04180609"},{"key":"10.1016\/j.lpm.2011.08.001_bib0260","doi-asserted-by":"crossref","unstructured":"de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009, [ASN 2008111205].","DOI":"10.1681\/ASN.2008111205"},{"key":"10.1016\/j.lpm.2011.08.001_bib0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000052609","article-title":"Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease","volume":"9","author":"Torres","year":"2001","journal-title":"Exp Nephrol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821100409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821100409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T16:34:03Z","timestamp":1638981243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075549821100409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S075549821100409X"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.08.001","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}